Jefferies upgraded Fisher & Paykel Healthcare to Buy from Hold with a price target of NZ$40.90, up from NZ$39.40. Fisher & Paykel successfully converted clinical change into product sales through FY25, even with a moderate flu season, says the firm, which believes limited tariff impacts and the company’s practice of continuous process improvement should lead to increased operating leverage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare downgraded to Underperform at RBC Capital
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution
- Fisher & Paykel Healthcare Achieves Record Revenue in 2025
- Fisher & Paykel Healthcare Announces Investor Event in Melbourne